June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Brimonidine drug delivery system (Brimo DDS Generation 1) slows the growth of retinal pigment epithelial hypofluorescence following regional blue light irradiation in a nonhuman primate (NHP) model of geographic atrophy (GA)
Author Affiliations & Notes
  • Corine Ghosn
    Allergan plc, Irvine, California, United States
  • Alexandra Almazan
    Allergan plc, Irvine, California, United States
  • Sherri Decker
    Allergan plc, Irvine, California, United States
  • James A Burke
    Allergan plc, Irvine, California, United States
  • Footnotes
    Commercial Relationships   Corine Ghosn, Allergan plc (E); Alexandra Almazan, Allergan plc (E); Sherri Decker, Allergan plc (E); James Burke, Allergan plc (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1960. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Corine Ghosn, Alexandra Almazan, Sherri Decker, James A Burke; Brimonidine drug delivery system (Brimo DDS Generation 1) slows the growth of retinal pigment epithelial hypofluorescence following regional blue light irradiation in a nonhuman primate (NHP) model of geographic atrophy (GA). Invest. Ophthalmol. Vis. Sci. 2017;58(8):1960.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age related macular degeneration involves GA of the retinal pigment epithelium (RPE), loss of photoreceptors and visual impairment. The aim of this pilot study was to investigate if Brimo DDS Gen 1 slows the loss of RPE and photoreceptors in a NHP model of GA.

Methods : Three 5 mm diameter parafoveal lesions were made in 12 eyes of 6 female Cynomolgus monkeys using a light source with a 470 nm filter. Fundus autofluorescence, optical coherence tomography and multifocal electroretinography (mfERG) were performed at baseline and at 1, 2, 4, 8, 12, 16, and 20 weeks post lesion. RPE loss was measured as hypofluorescence within the lesion automatically by referencing the fovea, (darkest area) and applying a pixel intensity cutoff. Photoreceptor structure and function were evaluated as outer nuclear layer (ONL) thickness and mfERG b-wave amplitude, respectively. Hypofluorescence within the lesion increased over time indicating progression. Five weeks post injury 4 monkeys received intravitreal 132 μg of Brimo DDS Gen 1 unilaterally, while the fellow eye received placebo DDS. Two additional monkeys (control; OU) were not dosed but followed-up at the same time points. A two-way repeated measures ANOVA with multiple comparisons (Tukey) was used to compare the effects of drug and duration.

Results : No significant between group difference was observed in the measures prior to dosing. At 3 weeks post dosing area of hypofluorescence was significantly less in the Brimo DDS eyes (13602 ± 1513) compared to control (18756 ± 1039). At 7 weeks post dosing Brimo DDS (14760 ± 2616) was significantly different from both placebo DDS (22681 ± 758) and control eyes (23782 ± 1587) and remained significantly decreased throughout study duration (20 weeks; p<0.05). mfERG b-wave amplitude showed significantly less reduction in Brimo DDS eyes (33.6 ± 5.3%) compared to placebo (55.5 ± 3.4%) at 12 weeks. Brimo DDS showed decreased ONL thinning from baseline (30.3 ± 2.3%) compared to placebo (38.1 ± 1.0%; p>0.05) and control eyes (43.2 ± 4.6%; p<0.05) at 20 weeks.

Conclusions : Brimo DDS slows the increase of hypofluorescence and reduction of mfERG b-wave amplitude following regional blue light irradiation in NHP indicating that Brimo DDS exhibits protective effects in the RPE and photoreceptors.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×